| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919295 | Radiotherapy and Oncology | 2012 | 6 Pages |
Abstract
In the management of node negative T1-T2 anal cancer, LRC and CSS tend to be superior in patients treated by combined CRT, even though the difference was not significant. Randomized studies are warranted to assess definitively the role of combined treatment in early-stage anal carcinoma.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Thomas Zilli, Ulrike Schick, Mahmut Ozsahin, Pascal Gervaz, Arnaud D. Roth, Abdelkarim S. Allal,